The Parkinson's disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo

dc.contributor.authorMorató Arús, Xavier
dc.contributor.authorLuján, Rafael
dc.contributor.authorLópez-Cano, Marc
dc.contributor.authorGandía Sánchez, Jorge
dc.contributor.authorStagljar, Igor
dc.contributor.authorWatanabe, Masahiko
dc.contributor.authorCunha, Rodrigo A.
dc.contributor.authorFernández Dueñas, Víctor
dc.contributor.authorCiruela Alférez, Francisco
dc.date.accessioned2018-04-30T12:35:31Z
dc.date.available2018-04-30T12:35:31Z
dc.date.issued2017-08-25
dc.date.updated2018-04-30T12:35:31Z
dc.description.abstractG protein-coupled receptor 37 (GPR37) is an orphan receptor associated to Parkinson's disease (PD) neuropathology. Here, we identified GPR37 as an inhibitor of adenosine A2A receptor (A2AR) cell surface expression and function in vivo. In addition, we showed that GPR37 and A2AR do oligomerize in the striatum. Thus, a close proximity of GPR37 and A2AR at the postsynaptic level of striatal synapses was observed by double-labelling post-embedding immunogold detection. Indeed, the direct receptor-receptor interaction was further substantiated by proximity ligation in situ assay. Interestingly, GPR37 deletion promoted striatal A2AR cell surface expression that correlated well with an increased A2AR agonist-mediated cAMP accumulation, both in primary striatal neurons and nerve terminals. Furthermore, GPR37−/− mice showed enhanced A2AR agonist-induced catalepsy and an increased response to A2AR antagonist-mediated locomotor activity. Overall, these results revealed a key role for GPR37 controlling A2AR biology in the striatum, which may be relevant for PD management.
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec679446
dc.identifier.issn2045-2322
dc.identifier.pmid28842709
dc.identifier.urihttps://hdl.handle.net/2445/121969
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-017-10147-x
dc.relation.ispartofScientific Reports, 2017, vol. 7, num. 1, p. 9452
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/604102/EU//HBP
dc.relation.urihttps://doi.org/10.1038/s41598-017-10147-x
dc.rightscc-by (c) Morató Arús, Xavier et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationMalaltia de Parkinson
dc.subject.classificationProteïnes G
dc.subject.classificationAdenosina
dc.subject.classificationMarcadors bioquímics
dc.subject.classificationReceptors de neurotransmissors
dc.subject.otherParkinson's disease
dc.subject.otherG Proteins
dc.subject.otherAdenosine
dc.subject.otherBiochemical markers
dc.subject.otherNeurotransmitter receptors
dc.titleThe Parkinson's disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
679446.pdf
Mida:
2.4 MB
Format:
Adobe Portable Document Format